The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

(2019) Xuan Jiang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation

(2018) Isabella Faraoni et al.   CANCER LETTERS

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Yung-Jue Bang et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression

(2014) X. Wei Meng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity

(2013) Antonio Macciò et al.   EXPERT OPINION ON PHARMACOTHERAPY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET